Genmab — Januar 2025
-
@Sukkeralf det er ikke nødvendigvis en VP fra Solid oncology. Tråden jeg linkede til var lang og gammel, og jeg tror godt det kunne være i den overordnede oncology vifte at denne VP er fyret/har sagt op.
-
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches https://www.sciencedirect.com/science/article/pii/S1044532324000605
-
-
Her er en jeg synes var interessant. En ny platform til at fintune T-cell engagers:https://pmc.ncbi.nlm.nih.gov/articles/PMC11322607/
-
"We show that initial bsAb mediated contact of a few T-cells with a 3D cluster of tumor cells embedded within a fibrillar ECM, resembling a tumor microenvironment in which solid tumors, including breast cancers grow and invade, only leads to a full-blown immune attack if a subsequent wave of T-cell recruitment is triggered."
-
Kiggede lidt på COLUMBA (Dara SC vers. IV i RRMM). Egentlig interessant nok, at "DARA SC and DARA IV continue to demonstrate similar efficacy and safety" .Der er andre fordele ved SC, men faktisk ikke på effekt og varighed.https://pmc.ncbi.nlm.nih.gov/articles/PMC9521240/
-
Av for den Topsøe. Mindes der blevet lavet peer på Epco-partnerskabet, dengang Topsøe købte sig ind i IGM. Det giver nok en større straksnedskrivning. Syns ikke Winkel har indikeret stop for Epco og IA, men nærmere, at det "selvfølgelig" skal undersøges sammen med Abbvie.
-
Jeg har bare kigget lidt på det, da jeg egentlig troede, at Erzo versus SC ville være sværere end versus IV. Også lidt bemærkelsesværdigt i forhold til hele diskussionen om, hvordan SC overhovedet er blevet godkendt som særskilt produkt, når det i effekt og varighed slet ikke adskiller sig
-
estimated market opportunity for bi specifics
in # of US patients https://x.com/paras_biotech/status/1878116633278841154/photo/1 -
HOT OFF THE PRESS!! #Hematology
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial https://x.com/DrRaulCordoba/status/1878135989790511471 https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible
-
Raul Cordoba, MD, PhD
@DrRaulCordoba
Impressive results of #epcoritamab + GEMOX in transplant ineligible R/R DLBCL patients with ORR/CR 85%/61% and even better if given in 2L with ORR/CR 90/74% #lymsm https://x.com/DrRaulCordoba/status/1878148690822541621
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind